CYSLTR2

Chr 13

cysteinyl leukotriene receptor 2

Also known as: CYSLT2, CYSLT2R, GPCR21, HG57, HPN321, KPG_011, PSEC0146, hGPCR21

The protein is a G protein-coupled receptor that binds cysteinyl leukotrienes (LTC4, LTD4, and LTE4) and activates phosphatidylinositol-calcium signaling, playing a major role in endocrine and cardiovascular systems. Mutations in this gene cause uveal coloboma with cleft lip and palate, which follows an autosomal recessive inheritance pattern. The condition affects ocular development and craniofacial structures during embryogenesis.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
11
Pubs (1 yr)
61
P/LP submissions
0%
P/LP missense
1.77
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryCYSLTR2
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
61 unique Pathogenic / Likely Pathogenic· 52 VUS of 128 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.77LOEUF
pLI 0.000
Z-score 0.02
OE 0.99 (0.541.77)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.12Z-score
OE missense 0.98 (0.861.11)
175 obs / 179.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.99 (0.541.77)
00.351.4
Missense OE0.98 (0.861.11)
00.61.4
Synonymous OE0.92
01.21.6
LoF obs/exp: 6 / 6.1Missense obs/exp: 175 / 179.4Syn Z: 0.56
DN
0.80top 10%
GOF
0.79top 25%
LOF
0.2093th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

128 submitted variants in ClinVar

Classification Summary

Pathogenic59
Likely Pathogenic2
VUS52
Likely Benign8
Benign7
59
Pathogenic
2
Likely Pathogenic
52
VUS
8
Likely Benign
7
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
59
0
59
Likely Pathogenic
0
0
2
0
2
VUS
0
49
3
0
52
Likely Benign
0
7
0
1
8
Benign
0
4
0
3
7
Total060644128

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CYSLTR2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Oncogenic signaling in uveal melanoma.
Park JJ et al.·Pigment Cell Melanoma Res
2018Review
Skin-homing basophils and beyond.
Shibuya R et al.·Front Immunol
2022
The Genetics of Uveal Melanoma: Overview and Clinical Relevance.
Riechardt AI et al.·Klin Monbl Augenheilkd
2021Review
Top 5 results · since 2015Search PubMed ↗